Mipsagargin: Phase II started

Inspyr said an investigator began an open-label, U.S. Phase II trial to evaluate IV mipsagargin given on days 1-3 of a 28-day cycle for 3 cycles in about 18 newly diagnosed patients prior to surgical ...